Jun 2026 (Q2 FY26) — Aug 10, 2026
TELA Bio Q2 FY26 — Revenue Miss and Guidance Withdrawal Amidst Sales Force and Competitive Headwinds
Read the full callTELA Bio (TELA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
TELA Bio earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 19.3 | −4.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -48.1 | −3.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -11.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.97 −1.02% · −$0.01
Performance −36.6% 1Y
1Y: $1.53 on 17 Oct 2025 → $0.97. High $1.53 (17 Oct 2025), low $0.56 (30 Mar 2026).
- Previous close
- $0.98
- 52-week range
- $0.56 – $1.51
- One year
- −34.46%
Overview
- Symbol
- TELA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
TELA Bio earnings calls (TELA)
Financials
What the filings say
Net profit, year on year: −13% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 18 | 19 | 20 | 21 | 21 | 19 | 19 |
| Operating profit | -9 | -8 | -10 | -9 | -8 | -7 | -11 | -9 |
| Operating margin | −49.4% | −47.3% | −56.5% | −45.0% | −36.5% | −31.9% | −55.2% | −48.1% |
| Other income | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | -10 | -9 | -11 | -10 | -9 | -9 | -12 | -11 |
| Tax rate | — | — | −0.5% | −0.3% | — | −1.6% | −0.5% | −0.5% |
| Net profit | -10 | -9 | -11 | -10 | -9 | -9 | -12 | -11 |
| EPS ($ per share) | -0.42 | — | -0.25 | -0.22 | -0.19 | — | -0.21 | -0.20 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -138 | -168 | -197 | -230 | -274 | -321 | -359 | -398 |
| Total liabilities | 41 | 37 | 37 | 42 | 54 | 59 | 58 | 75 |
| Fixed assets | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Investments | — | 9 | 0 | — | — | — | — | — |
| Total assets | 27 | 68 | 86 | 63 | 68 | 78 | 87 | 81 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -20 | -26 | -24 | -30 | -41 | -41 | -42 | -28 |
| Cash from investing | -2 | -12 | 9 | -1 | -2 | -1 | 4 | 1 |
| Cash from financing | 27 | 66 | 44 | 1 | 41 | 46 | 43 | 26 |
| Net cash flow | 6 | 28 | 29 | -30 | -2 | 5 | 6 | -2 |
| Capital expenditure | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -0 |
| Free cash flow | -20 | -26 | -25 | -31 | -42 | -41 | -43 | -29 |
Insider filings
39 filings between Oct 31, 2025 and Sep 17, 2026.
Open market
decisions to buy or sellPurchases
$4.19M
7 purchases by 3 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 20
- Award — granted as compensation
- 12
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| EW HEALTHCARE PARTNERS FUND 2, L.P. | $4.00M | — | Nov 17, 2025 |
| Capper Joseph H | $167.2K | — | Sep 17, 2026 |
| Getz Heather C | $18.8K | — | Aug 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Capper Joseph H Director | Purchase | 25,000 | $30.5K |
| Sep 16, 2026 | Capper Joseph H Director | Purchase | 50,000 | $58.3K |
| Sep 15, 2026 | Capper Joseph H Director | Purchase | 50,000 | $52.9K |
| Sep 14, 2026 | Capper Joseph H Director | Purchase | 25,000 | $25.5K |
| Aug 17, 2026 | Getz Heather C Chief Executive Officer | Purchase | 12,500 | $8.3K |
| Aug 14, 2026 | Getz Heather C Chief Executive Officer | Purchase | 15,000 | $10.5K |
| Aug 3, 2026 | Getz Heather C Chief Executive Officer | Award | 500,000 | $0 |
| Jul 15, 2026 | Capper Joseph H Director | Award | 6,227 | $4.9K |
| Jul 15, 2026 | Plovanic William J. Director | Award | 20,930 | $16.4K |
| Jun 9, 2026 | NEELS GUIDO J Director | Award | 11,925 | $0 |
| Jun 9, 2026 | NEELS GUIDO J Director | Award | 11,675 | $0 |
| Jun 9, 2026 | Capper Joseph H Director | Award | 11,925 | $0 |
| Jun 9, 2026 | Capper Joseph H Director | Award | 11,675 | $0 |
| Jun 9, 2026 | Plovanic William J. Director | Award | 11,675 | $0 |
| Jun 9, 2026 | Rocchio Betty Jo Director | Award | 11,675 | $0 |
| Jun 9, 2026 | NOHRA GUY P Director | Award | 11,925 | $0 |
| Jun 9, 2026 | NOHRA GUY P Director | Award | 11,675 | $0 |
| Jun 9, 2026 | THOMAS PAUL Director | Award | 11,675 | $0 |
| Jun 9, 2026 | THOMAS PAUL Director | Award | 11,925 | $0 |
| Feb 24, 2026 | KOBLISH ANTONY Chief Executive Officer | Tax withheld | 3,900 | $3.1K |
| Feb 23, 2026 | KOBLISH ANTONY Chief Executive Officer | Tax withheld | 11,631 | $8.9K |
| Feb 23, 2026 | Cuca Roberto COO and CFO | Tax withheld | 5,234 | $4.0K |
| Feb 23, 2026 | Talmo Paul Chief Technology Officer | Tax withheld | 4,061 | $3.1K |
| Feb 23, 2026 | Smeykal Megan Chief Accounting Officer | Tax withheld | 423 | $324 |
| Feb 23, 2026 | Firestone Gregory A. Chief Business Officer | Tax withheld | 1,352 | $1.0K |
| Feb 21, 2026 | Smeykal Megan Chief Accounting Officer | Tax withheld | 1,590 | $1.1K |
| Feb 21, 2026 | KOBLISH ANTONY Chief Executive Officer | Tax withheld | 12,494 | $9.0K |
| Feb 21, 2026 | Firestone Gregory A. Chief Business Officer | Tax withheld | 4,189 | $3.0K |
| Feb 21, 2026 | Cuca Roberto COO and CFO | Tax withheld | 4,780 | $3.4K |
| Feb 21, 2026 | Talmo Paul Chief Technology Officer | Tax withheld | 3,385 | $2.4K |
| Feb 20, 2026 | KOBLISH ANTONY Chief Executive Officer | Award | 176,000 | $0 |
| Feb 20, 2026 | Cuca Roberto COO and CFO | Award | 57,000 | $0 |
| Feb 20, 2026 | Blizard Jeffrey President | Award | 86,000 | $0 |
| Feb 20, 2026 | Talmo Paul Chief Technology Officer | Award | 57,000 | $0 |
| Feb 20, 2026 | Firestone Gregory A. Chief Business Officer | Award | 37,000 | $0 |
| Feb 19, 2026 | Smeykal Megan Chief Accounting Officer | Tax withheld | 795 | $632 |
| Feb 18, 2026 | Smeykal Megan Chief Accounting Officer | Award | 32,850 | $0 |
| Nov 17, 2025 | EW HEALTHCARE PARTNERS FUND 2, L.P. 10% owner | Purchase | 3,604,000 | $4.00M |
| Oct 31, 2025 | Plovanic William J. Director | Award | 11,925 | $0 |
| Oct 9, 2025 | Rocchio Betty Jo Director | Award | 11,925 | $0 |
| Aug 3, 2025 | Firestone Gregory A. Chief Commercial Officer | Tax withheld | 1,093 | $2.0K |
| Jun 2, 2025 | Blizard Jeffrey President | Award | 104,800 | $0 |
| May 28, 2025 | EVANS DOUGLAS G Director | Award | 7,950 | $0 |
| May 28, 2025 | O'Brien Federica F. Director | Award | 7,950 | $0 |
| May 28, 2025 | Azarbarzin Kurt Director | Award | 7,950 | $0 |
| May 28, 2025 | Blizard Jeffrey Director | Award | 7,950 | $0 |
| May 28, 2025 | Burgess Vincent J Director | Award | 7,950 | $0 |
| May 28, 2025 | COLLERAN LISA N Director | Award | 7,950 | $0 |
| Mar 31, 2025 | KOBLISH ANTONY Chief Executive Officer | Tax withheld | 384 | $468 |
| Mar 31, 2025 | Talmo Paul Chief Technology Officer | Tax withheld | 190 | $232 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TELA Bio, Inc.
Free account. Everything above stays public.
Write why you follow TELA Bio, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading